StockData

Nektar Therapeutics vs Zymeworks

NKTR and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NKTR and ZYME compare

Zymeworks is the larger company, worth 1.5 times as much as Nektar Therapeutics ($1.9B against $1.2B).

Nektar Therapeutics grew revenue faster over the last twelve months (−43.9% versus −69.8% for Zymeworks).

Nektar Therapeutics keeps more of each dollar of sales as profit, with a net margin of −297% compared with −404% at Zymeworks.

Nektar Therapeutics scores higher on the StockData Score (9 against 5 for Zymeworks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNKTRZYME
Size and price
Market cap$1.2B$1.9B
Share price$36.44$26.45
Change, 1 year−32.5%43.0%
Change, 5 years−78.3%35.6%
Beta (5Y)0.630.28
Employees63264
StockData Score
Total score9 (better)5
Valuation score1 (better)0
Growth score1 (better)0
Performance score2 (better)0
Health score55
Dividend score00
Valuation
P/S22.5× (better)50.6×
P/B1.4× (better)23.4×
FCF yield−16.8%−6.4% (better)
Fair value–$3.39
Margin of safety–−680%
Growth
Revenue growth (TTM)−43.9% (better)−69.8%
Revenue growth, 5Y average−18.4%22.2% (better)
Profitability
Gross margin100%–
Operating margin−254% (better)−419%
Net margin−297% (better)−404%
FCF margin−378%−325% (better)
Return on equity−37.3% (better)−72.3%
Return on invested capital−1186%−179% (better)
Financial health
Debt / equity0.000.00
Current ratio10.42 (better)6.32
Altman Z-score−0.67 (better)−1.01
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield0.00%9.0% (better)
Shareholder yield0.00%9.0% (better)
Ownership
Held by institutions105%98.1%
Held by insiders0.46%58.9%
Insider net buying, 12 months−$2.2M (better)−$5.0M
Short interest, % of float19.9%20.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.